MedTrace Logo

The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD

NCT01554462 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2013-12-11

No results posted yet for this study

Summary

Forty children with and 40 children without Attention deficit Hyperactivity Disorder (ADHD) receive Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) or placebo via a dietary intervention. Cognitive control functions are measured with functional Magnetic Resonance Imaging (MRI) before and after the intervention. Behavioural change is monitored with behavioural scales.

Conditions

  • Attention Deficit Hyperactivity Disorder
  • Healthy

Interventions

DIETARY_SUPPLEMENT

Eicosapentaenoic acid / Docosahexaenoic acid

650 mg EPA + 650 mg DHA daily

DIETARY_SUPPLEMENT

Placebo dietary intervention (MUFA) in ADHD group

Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value

DIETARY_SUPPLEMENT

Eicosapentaenoic acid / Docosahexaenoic acid

650 mg EPA and 650 mg DHA daily

DIETARY_SUPPLEMENT

Placebo dietary intervention (MUFA) in healthy control group

Placebo contains MUFA in stead of PUFA, same energy value

Sponsors & Collaborators

  • UMC Utrecht

    collaborator OTHER

  • Unilever R&D

    lead INDUSTRY

Principal Investigators

  • Marco Hoeksma, PhD · Unilever Research Vlaardingen

  • Sarah Durston, PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554462 on ClinicalTrials.gov